How Axium grew 10x and became Kroger's entry into specialty pharmacy
Roughly $50M to roughly $500M. An acquisition by the fifth largest pharmacy operator in the country. And a management team the acquirer chose to keep.
Nothing about this company was broken
By 2010, Axium Healthcare Pharmacy had spent a decade doing the hard part well.
It entered a still young specialty pharmacy market in 2000 treating patients with hepatitis C, built around a vision its founders repeated until it became operating policy: improve outcomes one relationship at a time. A decade later it was a nationally recognized specialty pharmacy with locations across the United States and in Puerto Rico, supporting more than thirteen chronic and rare conditions including oncology, multiple sclerosis, Crohn's disease, and rheumatoid arthritis.
Doctors of pharmacy. Registered nurses. Patient care coordinators. Reimbursement specialists. The clinical model worked, the outcomes were real, and the company was doing roughly $50 million in revenue.
It was also four years into private equity ownership. In 2006, Carousel Capital partnered with Mark Montgomery and the management team to complete a management buyout, recapitalizing out two founders who held more than 90 percent of the business and were not involved in daily operations. By 2010 the company had professional management, a sponsor, and a clock.
Nothing about that was broken. Axium had simply outgrown the way it grew.
Operationally strong. Commercially invisible.
Specialty pharmacy was growing 17 percent a year and already accounted for a quarter of national prescription drug spending. Demand was the loud problem, and operations, therapy categories, and headcount had all scaled to meet it. The commercial side had not. Marketing was reactive. Positioning, messaging, and brand elements had drifted apart across teams. Materials were produced ad hoc by sales reps and clinical staff who knew the industry cold and had never been asked to build a market position.
The result was a company that performed better than it appeared.
In a category heading toward consolidation, that gap gets expensive in a specific way. Buyers, partners, and manufacturers were all running the same evaluation, and none of them could see what made Axium different quickly enough for it to matter. When a market cannot tell two good companies apart, it prices them the same. So does a buyer.
Being good is not a position. It is a starting point that erodes.
The decision most companies get backwards
Most companies invest in commercial identity after growth slows. Axium did it while growth was accelerating.
In 2010 the business was growing, the category was expanding, and every rational argument pointed toward putting resources into operations and clinical capacity to keep up with demand. Leadership built the commercial system in parallel instead, on the theory that the window to define a position closes as a category consolidates, not after.
They were right about the window. The category consolidated within two years.
The work
Legacy DNA partnered with Axium in August 2010 and did not leave when the company changed hands. We stayed through the Kroger acquisition, through the ModernHEALTH combination in 2016, and into the early formation of Kroger Specialty Pharmacy and Kroger Infusion Pharmacy. The acquirer kept the relationship, which is its own kind of evidence.
A position built on what they were genuinely better at. Axium's strengths were real and buried. Most of what a company is proud of is not what a customer or a buyer is choosing on. We worked with leadership to find the few things Axium was actually better at than anyone else in the category and built the position on those. Differentiation became visible at a glance, without a conversation required to explain it.
One commercial identity, carried by everyone. Before, the story depended on who happened to be telling it. After, there was a single narrative leadership could carry into a manufacturer negotiation, a payer conversation, or a buyer meeting, and it described something the company actually did. Buyers discount companies when the external story does not match internal reality.
The infrastructure to scale demand. A rebuilt digital presence, original content for patients, providers, payers, and manufacturers, capability presentations for managed care, and the field materials that had previously been improvised. Growth stopped depending on individual effort.
A customer experience the market could see. The OnePlace patient and provider portal gave prescribers and patients a single place to work with Axium, and it moved market share during the peak of the hepatitis C product cycle.
Mark Montgomery and the management team had built the clinical model, the operating discipline, and the leadership depth before we arrived. Those are the things a buyer ultimately pays for. What we owned was the translation, and translation is what decides how a buyer values a company that is already good.
"Dr. Roxie and the Legacy DNA team has been the cornerstone of partnering with Axium Healthcare to create a national brand in the specialty pharmacy industry. They played a key role in strategy, mission and value creation for the organization."
Mark Montgomery, then Chief Executive Officer, Axium Healthcare Pharmacy
What held
On December 6, 2012, The Kroger Co. acquired Axium Pharmacy Holdings from Carousel Capital. Kroger is the fifth largest pharmacy operator in the country, and Axium was its entry into specialty pharmacy.
Axium continued to operate as an independent company inside Kroger, led by Mark Montgomery and the same management team. In 2016 it acquired ModernHEALTH to form the business that operates today as Kroger Specialty Pharmacy.
The growth to roughly $500 million happened before Axium had fully leveraged the Kroger customer base. Once it did, the platform went on to exceed $2 billion in revenue. The position held, the leadership held, and what Kroger bought was still working when the acquirer put its own distribution behind it. That is the only real test of whether commercial value was built into a business or layered on top of it.
And then the story closed a loop nobody planned
In March 2024, Kroger agreed to sell its specialty pharmacy business to CarelonRx, Elevance Health's pharmacy benefit manager. The $464 million transaction closed in October 2024. Through 2025, CarelonRx integrated the Kroger Specialty Pharmacy footprint into its specialty platform.
That platform is BioPlus.
The same CEO, twice. Mark Montgomery led Axium when we started. He later led BioPlus and brought us with him, and took the company through the Elevance integration. We spent six years building Axium's commercial identity starting in 2010, then seven inside BioPlus, where Dr. Roxie Mooney held the CMO seat as an outside operator from 2018 to 2025 while Legacy DNA was agency of record. We are still agency of record at BioPlus and under contract today.
Fourteen years after we helped make Axium legible to a buyer, the business it became was absorbed into the business we had spent the intervening years building, under the same CEO, with us on both sides of the integration.
Two companies. Four owners. One business today.
Nobody engineers that. But it is the clearest evidence we have of what this work is for. Commercial systems built properly do not just survive a transaction. They keep being the thing that other businesses get folded into.
The outcome
Revenue from roughly $50M to roughly $500M over a six year partnership
Acquired by The Kroger Co. in December 2012, its entry into specialty pharmacy
The same CEO and management team ran the business after the sale
$2B in platform revenue under Kroger ownership as Kroger Specialty Pharmacy
New manufacturer contracts won on the strength of position rather than price
2011 SMART Award in Healthcare and Life Sciences, ACG Orlando
Named to the Inc. 500|5000 list of America's fastest growing private companies
2013 Ernst and Young Entrepreneur of the Year Award
Legacy DNA agency of record through the acquisition, and still under contract at BioPlus today
"I've worked alongside Roxie for more than 15 years, through growth, through pressure, through exit. She's been in the room when the decisions were hard and the stakes were real. That kind of outcome doesn't come from effort alone. It comes from understanding how to make what you've built undeniable to the market."
Mark Montgomery, Former CEO, Axium Healthcare Pharmacy and BioPlus Specialty Pharmacy, in the foreword to Winning in Healthcare
What this means for your company
Strong operations are necessary and not sufficient. Nobody acquires effort. Buyers acquire clarity about how value is created, confidence that it is repeatable, and conviction that it transfers to someone who was not there when it was built.
Axium had all three underneath the surface. The work was making them visible before the category consolidated and the window closed. That is what exit readiness actually is, and it is built years before anyone uses the phrase.
That work is what the Enterprise Value Creation System™ sequences. See the framework here.
Start with a Strategic Fit Call
Forty-five minutes. No pitch. You'll know quickly whether this is a fit.